Sphingosine-1-phosphate (S1P) modulates various cellular functions such as apoptosis, cell differentiation, and migration. Although S1P is an abundant signaling molecule in the central nervous system, very little is known about its influence on neuronal functions. We found that S1P concentrations were selectively decreased in the cerebrospinal fluid of adult rats in an acute and an inflammatory pain model. Pharmacological inhibition of sphingosine kinases (SPHK) decreased basal pain thresholds and SphK2 knockout mice, but not SphK1 knockout mice, had a significant decrease in withdrawal latency. Intrathecal application of S1P or sphinganine-1-phosphate (dihydro-S1P) reduced the pain-related (nociceptive) behavior in the formalin assay. S1P and dihydro-S1P inhibited cyclic AMP (cAMP) synthesis, a key second messenger of spinal nociceptive processing, in spinal cord neurons. By combining fluorescence-resonance-energytransfer (FRET)-based cAMP measurements with Multi-Epitope-Ligand-Cartography (MELC), we showed that S1P decreased cAMP synthesis in excitatory dorsal horn neurons. Accordingly, intrathecal application of dihydro-S1P abolished the cAMP-dependent phosphorylation of NMDA receptors in the outer laminae of the spinal cord. Taken together the data show that S1P modulates spinal nociceptive processing through inhibition of neuronal cAMP synthesis.
The bioactive sphingolipid metabolite sphingosine-1-phosphate (S1P) is synthesized by phosphorylation of sphingosine by sphingosine kinases (SPHK) in a wide variety of cell types in response to extracellular stimuli such as nerve growth factor or vascular endothelial growth factor. S1P modulates diverse cellular functions such as apoptosis, cell differentiation, and migration either through the activation of a family of five G-protein coupled receptors (S1P [1] [2] [3] [4] [5] or by acting as an intracellular second messenger (1) (2) (3) . In the central nervous system S1P has been shown to be released by cerebellar granule cells and astrocytes (4) (5) (6) .
Regarding its function in the central nervous system it is well known that S1P promotes survival of neurons and astrocytes, induces proliferation of neural progenitor cells and astrocytes, and mediates nerve growth factor (NGF)-stimulated neurite outgrowth (2, 3, 7) . However, very little is known about the role of S1P in the regulation of neuronal excitability and the mechanisms that mediate these S1P functions. Recently whole-cell patch-clamp recordings revealed that loss of S1P 2 leads to a large increase in the excitability of neocortical pyramidal neurons (8) suggesting an inhibitory effect of S1P 2 on neuronal excitability. On the other hand several in vitro studies show that S1P can also increase neuronal functions. For example, S1P receptor activation augments glutamate secretion in hippocampal neurons (9) and elevated intracellular S1P concentrations enhance the spontaneous neurotransmitter release at neuromuscular junctions (10) . Furthermore, intra-as well as extracellularly applied S1P facilitated the NGF-induced increases in the excitability of sensory neurons from dorsal root ganglia (DRG) (11, 12) . However, to date little is known about physiological processes in which regulation of neuronal functions by S1P may play a role. Recently we showed that intrathecal administration of the S1P receptor agonist FTY720 reduces the nociceptive behavior in the formalin assay, demonstrating an antinociceptive effect of S1P receptor activation in the spinal cord (13) . Here, we investigated in vivo the role of S1P in the spinal cord on pain perception (nociception). We show that peripheral nociceptive stimulation decreases S1P concentrations in the cerebrospinal fluid and that inhibition of spinal S1P synthesis lowers pain thresholds. Moreover, elevated spinal S1P concentrations reduced the nociceptive behavior in the formalin test. Towards the mechanism of the anti-nociceptive actions of S1P, we found that S1P decreases the cAMP synthesis in excitatory spinal cord neurons and prevents the cAMP-dependent phosphorylation of NMDA receptors in the outer laminae of the dorsal horn. These data present for the first time in vivo evidence that S1P is involved in nociceptive processing and modulated neuronal cAMP synthesis.
Experimental procedures
Materials: S1P was purchased from Tocris (Ellisville, MO). N,N-dimethylsphingosine (NNDS), DL-threo-dihydrosphingosine (DHS) and sphinganine-1-phosphate from Sigma (St.Louis, MO). Antibodies: Antibodies used were directed against SPHK-1 (Orbigen, San Diego, CA), SPHK-2 (Abgent, San Diego, CA), nuclear neuronal protein (NeuN), CD146, glial fibrillary acid protein (GFAP) (all Chemicon, Temecula, CA), VGLUT-1 and-2 (Synaptic Systems, Göttingen, Germany), CD56 (neural cell adhesion molecule, N-CAM), 7-Amino Actinomycin D (7AAD) (both BD Pharmingen, San Jose, CA), IBA-1 (Wako, Richmond, VA), phospho897-NR1 und ATP synthase (Upstate-Millipore, Eschborn, Germany), phosphoT286 CamKII (Promega, Madison, WI) FITC-conjugated Griffonia simplicifolia isolectin B4 (IB4), FITC-conjugated phalloidin (both Sigma, St.Louis, MO). Primary antibodies against S1P [1] [2] [3] [4] [5] were generated by immunization of rabbits with the following peptides: S1P1-CRLTFRKNISKASRS, S1P2-ETLDMGETPSRKVAC, S1P3-CLAGRLRDPPEGSTL, S1P4-CLRPRDSFRTSRSLS, S1P5-CNARRLRAGPGSRRA by Sigma using their standard protocol. Animals: Sprague Dawley rats (250-300 g) were supplied by Charles River Wiga GmbH (Sulzfeld, Germany). In all experiments the ethics guidelines for investigations in conscious animals were obeyed and the procedures were approved by the local Ethics Committee. SPHK-1 and SPHK-2 knockout mice were kindly supplied by Novartis, Switzerland (14). RT-PCR: 2 µg of total RNA from rat spinal cord was annealed with 0.6 µM oligo(dT) primer and reversely transcribed using reverse transcriptase (Promega, Madison, WI) for 30 minutes at 37°C. Rat-specific oligonucleotides are based on the primers used for the amplification of human S1P receptors as published previously (15, 16) . (Primer:  S1P1:  CTTCAGCCTCCTTGCTATCG  and  GCAGGCAATGAAGACGACACTCA,  S1P2:  TTCTGGTGCTAATCGCAGTG  and  GAGCAGAGAGTTGAGGGTGG,  S1P3:  TCAGGGAGGGCAGTATGTTC  and  CTGACTCTTGAAGAGGATGG,  S1P4:  GTGCTCAACTCAGCCATCAA  and  CTGCCAAACATTCATCATGG,  S1P5: TGTTCCTGCTCCTGGGTAGT and GTTTCGGTTGGTGAAGGTGT) Sphingolipid concentrations in the cerebrospinal fluid: Sphingolipid concentrations in the cerebrospinal fluid were determined without prior extraction by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). HPLC analysis was done under gradient conditions using a Luna C18-column (150 cm L x 2 mm ID, Phenomenex, Aschaffenburg, Germany). MS/MS analyses were performed on a 4000 Q TRAP triple quadrupole mass spectrometer with a Turbo V source (Applied Biosystems, Darmstadt, Germany) as described previously (17) . Concentrations of the calibration standards, quality controls and samples were evaluated by Analyst software 1.4 (Applied Biosystems, Darmstadt, Germany). The coefficient of correlation for all measured sequences was at least 0.99. Variations in accuracy and intra-day and inter-day precision (n = 6 for each concentration, respectively) were <15% over the range of calibration.
Behavioral tests: Implantation of lumbar catheters was performed as described previously (18) with the exception that polyethylene catheters (0.28 mm inner diameter, 0.61 mm outer diameter, Neolab, Heidelberg, Germany) were used. The formalin assay (18) , and the hot plate test (19) were performed as described previously. The observer was unaware of the treatments in all tests. Primary cell cultures: Whole spinal cords or brains were collected from embryos 16 to 18 days post coitus and directly transferred into ice cold HBSS containing CaCl 2 and MgCl 2 as described previously (20) . Briefly, the spinal cords were treated with trypsin-EDTA and collagenase (500 U/ml, Biochrom AG, Germany) followed by mechanical separation. To obtain neuronal cultures, the cell suspension was plated on poly-L-lysinecoated dishes and incubated for 2 hours in neurobasal medium containing B-27 supplement, 10% foetal calf serum (FCS), 100 U/ml penicillin, 100 µg/ml streptomycin, and 2 mM L-glutamine (all from Invitrogen, Carlsbad, CA). After the cells became adherent, the medium was replaced and 0.01 µg/ml murine nerve growth factor (Invitrogen, Carlsbad, CA) was added. After 24 hours the medium was replaced by serum-free medium and incubated for another 6 days until the cAMP assays were performed. To generate glia cultures the cell suspension was cultivated in RPMI 1640, 10% FCS, 100 U/ml penicillin, and 100 µg/ml streptomycin. The cells were grown for at least 7 days and split at least twice. cAMP accumulation: cAMP amounts in primary spinal cord cells were determined as described previously (21) . For cAMP accumulation assays with freshly dissociated adult spinal cords, the dorsal half of the spinal cord from an adult rat was treated with 5 ml 0.1% collagenase in neurobasal medium containing B27 for 45 minutes at 37°C and then mechanically dissociated. Remaining tissue was allowed to sediment for 1 minute before the supernatant was centrifuged for 5 minutes at 90x g. The cells were washed twice with medium and then used for cAMP determinations. FRET imaging: Primary spinal cord cell cultures were plated on poly-L-lysine coated, photoetched coverslips (Dunn Labortechnik, Asbach, Germany) and transfected with pCDNA-CAT-CFP and pCDNA-RII-L20-YFP constructs (22) (20-22°C) and imaged on an Axioscope 2 upright microscope (Zeiss, Jena, Germany) with a 63x Achroplan water immersion objective (Zeiss). The microscope was equipped with an Imago CCD camera, a Polychrome IV monochromator (all TILL Photonics, Gräfelfing, Germany), and a beamsplitter optical device (Multispec Microimager, Optical Insights). Images were acquired and processed using Tillvision software. FRET changes were measured as changes in the backgroundsubtracted 480/545 nm fluorescence emission intensities on excitation at 430 nm and expressed as R/R 0 , where R is the ratio at time t and R 0 is the ratio at time =0 s. FRET signals were averaged over 20 s and the calculation of statistical descriptions and best-fit were achieved using Sigma Plot 8.0. Cells were incubated with 50 µM 3-isobutyl-1-methylxanthine (IBMX) and 25 µM forskolin and where indicated with 3 µM S1P. Phase contrast images of cells of interest and the square identification numbers of the photoetched coverslips were recorded to permit later identification of the cells in the MELC system. Calcium imaging: Calcium imaging experiments were performed with primary spinal cord neuronal cells (described under primary cell culture) plated on poly-L-lysine coated, photoetched coverslips for 3-6 days in culture. Prior to the determination of intracellular calcium levels ([Ca 2+ ] i ), cells were incubated with 10 µM of the ratiomeric calcium indicator Fura-2 AM (Biotium, Hayward, USA) in Neurobasal medium (Gibco) for 30 minutes at 37 °C and 5% CO 2 . Fura-2 loaded cells were washed twice with Neurobasal medium and transferred to the perfusion-chamber (same setup as described under FRET imaging) and imaged with a 40x Achroplan water immersion objective (Zeiss) at room temperature. [Ca 2+ ] i was expressed as the ratio of the background-subtracted fluorescence emission at 510 nm (filter type LP 440) due to excitation at 340 nm and 380 nm using the Polychrom IV Monochromator (Till Photonics). Cells were first stimulated with 40 mM KCL-Ringer for 1 second by puff application prior S1P application.
Multi epitope ligand cartography (MELC):
MELC robot technology involved validated distinct hardware and software components, as described earlier (23, 24) . After FRET imaging cells of interest were localized using the square identification number of the coverslips, the YFP-fluorescence and the phase contrast images. The primary spinal cord cells were fixed with 4% paraformaldehyd/PBS for 10 minutes, incubated for 10 min with 6 M guanidinium-HCl to remove YFP fluorescence and fixed again with 4% paraformaldehyd/PBS. Then the cells were permeabilized with 0.2% Triton-X100 for 10 min and incubated with normal goat serum (10%) for 60 min. The coverslip was placed onto a customized sample holder (2 mm thickness, inner diameter of 16 mm) and fixed with an adapted silicon ring (outer diameter 2 cm, inner diameter 1 cm) that also served as antibody incubation chamber. The sample was positioned onto the inverted fluorescence microscope (Leica DM IRE2; 63x oil objective lens). By a robotic pipetting process the specimen was incubated with fluorophore-labeled antibodies and wash solutions under temperature control. Phase contrast and fluorescence signals were recorded, followed by a bleaching step (488 nm for FITC and 546 nm for phycoerythrin). A postbleaching image was taken and subtracted from the image taken from the following epitope. Antibody labeling with FITC was performed as described previously (23, 24) and signals were validated using conventional immunohistochemistry. Recording and processing of all image data and the coordination of all system components were fully automatically controlled by software developed by MelTec GmbH (Magdeburg, Germany). Conventional immunohistochemistry: Cells as well as tissue slices were fixed in 4% paraformaldehyde in PBS for 10 minutes, permeablized in 0.1 % Triton X-100 for 5 minutes and blocked for 1 hour in 3% BSA in PBS. Primary and secondary antibody incubations were done in PBS containing 1% BSA for 1 hour each. The samples were washed 3x with PBS prior mounting. For analysis a Nikon Eclipse C600 fluorescence microscope (Nikon, by guest on November 9, 2016 http://www.jbc.org/ Downloaded from Duesseldorf, Germany) was used. Quantification of antibody signals on spinal cord slices was done using ImageJ 1.39 (NIH, USA) software. For each image the mean integrated density for the outer lamina II of the dorsal horn was determined according to IB4 staining and background corrected. Values for each spinal cord were acquired using 3-4 different slices and averaged. Data analysis: The statistical analysis was performed using Student's t-test and P-values of less than 0.05 were considered to be significant.
RESULTS

Spinal S1P concentrations are selectively decreased after peripheral nociceptive stimulation and modulate pain thresholds
First we determined the expression of SPHK-1 and -2 as well as the expression of the S1P receptors S1P [1] [2] [3] [4] [5] in the adult spinal cord. Both, SPHK-1 and SPHK-2, were detected by western blot analysis in spinal cord lysates (Fig. 1A) . The mRNA of all five S1P receptors (S1P [1] [2] [3] [4] [5] ) was detected by RT-PCR (Fig. 1B) in the spinal cord of adult rats and the expression of the respective proteins was confirmed by western blot analysis (Fig. 1C) . S1P itself as well as sphingosine and five ceramides were detectable by LC-MS/MS in the cerebrospinal fluid of naive adult animals ( Fig. 2A,B) . To investigate the effect of nociceptive stimulation on spinal S1P concentrations we employed two commonly used pain models. In the formalin model for acute pain, formalin is injected into one hind paw and the nociceptive behavior is recorded during one hour. In the second model zymosan is injected into one hind paw and the development of hyperalgesia is monitored over 8 hours. We found that S1P concentrations in the cerebrospinal fluid were significantly reduced in both pain models ( Fig. 2A) while the concentrations of all other detectable sphingolipids were not significantly altered (Fig. 2B) . Since in both pain models the S1P concentration in the cerebrospinal fluid decreased after nociceptive stimulation, we investigated whether a reduction of S1P synthesis facilitates the transmission of nociceptive signals. To reduce spinal S1P synthesis we intrathecally administered the SPHK inhibitors N,N-dimethylsphingosine (NNDS) and DL-threodihydrosphingosine (DHS). Owing to the fact that peripheral nociceptive stimulation alone decreases spinal S1P concentrations, we chose to determine the influence of the SPHK inhibitors on basal pain thresholds. 90 minutes after intrathecal application of NNDS or DHS, the rats exhibited significantly lower pain thresholds in the hot plate test as compared to control animals which received the respective vehicle (Fig. 2C) . Also, SPHK2 knockout mice had significantly lower pain thresholds in the hot plate test than wild type mice or mice with knockout of the gene for SPHK1 (Fig.  2D) . Thus, so far the data show that pain thresholds can be modulated by intrathecal administration of S1P, S1P reduction by sphingosine kinase inhibitors, or the absence of one of the sphingosine kinases that might produce endogenous S1P.
Spinal S1P concentrations modulate nociceptive behavior in the formalin assay To determine whether elevated spinal S1P concentrations reduce nociceptive processing, we administered S1P intrathecally and determined its effect in the formalin assay. Administration of 10 µl of 5 and 10 µM S1P-solutions decreased the nociceptive behavior dose-dependently (Fig. 3A,  B) . Surprisingly, this antinociceptive effect of S1P disappeared at higher S1P concentrations (40 µM; Fig. 3B ) which may have two reasons: First, at higher doses S1P may reach the DRGs and increase the excitability of sensory neurons within the DRG (11, 12) . Secondly, since high extracellular S1P concentrations are described to cause its uptake in cells (25) , the second messenger properties of S1P could facilitate neuronal excitability (12, 26) . To distinguish between both possibilities, we intrathecally administered sphinganine-1-phosphate (dihydro-S1P), a S1P-receptor agonist that has similar receptor affinities as S1P, but that does not mimic the intracellular second messenger properties of S1P (25, 27) . In contrast to S1P, intrathecally administered dihydro-S1P exhibited a linear concentration-dependency in the formalin assay even at high doses (Fig. 3C) suggesting that the loss of the antinociceptive actions of S1P at higher doses is based on the intracellular properties of S1P in spinal neurons rather than the activation of S1P receptors on DRGs. Since high intracellular S1P concentrations increased intracellular calcium concentrations (25) (26) (27) , we determined the effect of various S1P and dihydro-S1P concentrations on intracellular calcium concentrations of cultured spinal cord cells. Neurons were identified in these cultures by their response to high KCl concentrations, by morphology, and in part by immunocytochemistry. Physiological S1P concentrations (1 µM) increased intracellular calcium concentrations in a significant number of glia but not in neurons (Fig. 3D) while S1P concentrations of 0.1 µM or lower did not instigate a calcium response in either cell type. However, high S1P concentrations (10 µM) increased intracellular calcium concentrations in about 50% of the cells, neurons as well as glia (Fig.  3D,E) . Similar to the S1P, incubation with 1 µM dihydro-S1P increased intracellular calcium concentrations in a significant number of nonneuronal cells without triggering a response in a significant number of neurons (Fig. 3D) . Most importantly, in contrast to 10 µM S1P, we found no significant effects on intracellular calcium concentrations in neurons and glia using 10 µM dihydro-S1P (Fig. 3D) suggesting that the calcium response to 10 µM S1P is due to the second messenger properties of S1P. The lack of response of glia to 10 µM dihydro-S1P can be accounted to the desensitization of S1P receptors in presence of high agonist concentrations which is also observed with other receptors and further supports a receptorindependent effect of 10 µM S1P. Taken together the data suggest that high S1P concentrations cause its uptake in spinal cord cells and trigger an increase of intracellular calcium concentrations. Since the S1P-induced calcium responses enhance in certain neurons the neurotransmitter release (26) , high doses of intrathecally administered S1P may cause through the cellular uptake of S1P an increase of the transmission of nociceptive signals.
S1P inhibits cAMP synthesis in embryonic and adult primary spinal cord cells
All S1P receptors can inhibit adenylyl cyclases, the enzyme that catalyses the generation of cAMP, through activation of the inhibitory G-protein, G i (1-3) . Notably, cAMP is an important modulator of synaptic strength during nociceptive processing (28) (29) (30) (31) (32) . Therefore we tested whether S1P and dihydro-S1P decrease cAMP synthesis in spinal cord cells. Indeed, S1P inhibited concentrationdependently forskolin-stimulated cAMP synthesis in neuronal as well as in glia cultures (Fig. 4A) . Inhibition of cAMP accumulation was pertussis toxin-sensitive, indicating the involvement of S1P receptor-mediated G-protein activation (inset Fig.  4A ) Since β-adrenoceptors are predominantly expressed in neurons of the spinal cord (33), we used isoproterenol to stimulate more specifically the neuronal cAMP accumulation. In accordance with a predominant neuronal expression of β-adrenoceptors, the isoproterenol-evoked cAMP accumulation was 10fold lower in glia cultures as compared to the neuronal cultures (Fig. 4B) . S1P decreased isoproterenol-stimulated cAMP-synthesis concentration-dependently at between 0.1 and 1 µM while no effect was seen in glia cultures (Fig. 4B) . Isoproterenol-and forskolin-induced cAMP accumulation in the spinal cord cells was inhibited by dihydro-S1P with a similar concentrationdependency as compared to S1P (Fig. 4C) . Most importantly, the inhibitory effect of S1P on isoproterenol-stimulated cAMP accumulation seen in embryonic neurons was also observed in acute dissociated spinal cord cells from adult rats (Fig.  4D) .
S1P decreases cAMP synthesis in excitatory spinal cord neurons
To investigate whether S1P inhibits cAMP synthesis in neurons that participate in spinal nociceptive processing, we combined cAMP measurements by FRET imaging with a subsequent immunocytochemical analysis. First, we determined the effect of S1P on intracellular cAMP concentrations by monitoring FRET changes using two constructs (CFP-RIIβ and YFP-PKAc) encoding either the regulatory RIIα subunit coupled to the cyan (CFP) or the catalytic C-α subunit of PKA to the yellow (YFP) variants of the green fluorescent protein (22) . The constructs were cotransfected in primary spinal cord cells and FRET changes were recorded in presence of 50 µM IBMX and 25 µM forskolin. IBMX and forskolin were chosen to stimulate cAMP synthesis since this treatment increases the cAMP accumulation in all neurons independent of their subtype. In the transfected cells forskolin stimulation caused a maximal FRET change with a mean increase of R/R 0 of 1.23 ± 0.02. Due to the heterogeneity of the cellular population, the slope of the FRET changes ranged widely between the different cells, causing a relative big variation in the time to reach halfmaximal response (T 50 : 260.8 ± 83 seconds). In contrast, the variation in the onset of FRET changes, as defined as the time to reach 10% of the maximal response, was more homogenous (T 10 : 127.8 ± 41 seconds). Therefore in the following S1P-responding cells were defined as cells which exhibited a delay of at least 30% in the T 10 as compared to cells not receiving S1P. We found that S1P-treatment caused in about 40% of the investigated cells such a delay of T 10 . These S1P-responding cells showed in average a doubling of T 10 (Fig. 5B ) and a 30% delay in the T 50 in comparison to cells not receiving S1P or cells not responding to S1P (Fig. 5C ). The maximal FRET changes were not significantly reduced by S1P-treatment. To characterize the spinal cord neurons that respond to S1P, we used an immunocytochemical approach employing Multi-Epitope-Ligand-Carthography (MELC). MELC is an automated validated imaging technology that allows the consecutive detection of a large number of fluorophore-labeled primary antibodies on the same sample (23, 24, 34) . Briefly, in this method the application of each antibody is by guest on November 9, 2016 http://www.jbc.org/ Downloaded from followed by a wash and an imaging step. Then the fluorescence signal is bleached at the excitation wavelength and after acquisition of a postbleaching image, the next cycle is started. To characterize S1P responding cells we used cell-specific markers for astrocytes (GFAP), microglia (IBA1), endothelial cells (CD146), neurons (NeuN, CD56), and inhibitory (GAD67) as well as excitatory neurons (vesicular glutamate transporter (VGLUT)-1 and -2). 7AAD was used as nuclear marker and either phalloidin or the mitochondrial marker ATPsynthase as general cell marker. S1P receptor antibodies were not included, since the available antibodies were not suitable for the MELC system. We found that S1P-responding cells stained positively for the neuronal markers NeuN, CD56, and VGLUT-1 (Fig. 5D) supporting the results observed in the cAMP accumulation assays which suggested a neuronal response to S1P (Fig. 4A,B) . To define the location of these neurons in the spinal cord, we compared the expression patterns of VGLUT-1 and CD56 in spinal cord slices from adult and embryonic (E16) animals. In accordance with previous reports, we showed by colocalisation with the lamina II-marker IB4 a CD56-staining of lamina I-III of the dorsal horn as ( (35) and Fig. 5E ). VGLUT1-expression was observed in the deeper laminae of the dorsal horn beginning at lamina II and III ( Fig. 5E and (36) ). The same expression patterns of VGLUT-1 and CD56 were seen in spinal cords from embryonic rats (supplemental data 2) demonstrating that the expression of VGLUT-1 and CD56 does not differ between E16 embryonic and adult spinal cords. Since excitatory neurons located in lamina II and III are involved in spinal nociceptive processing (37) (38) (39) , a reduced cAMP synthesis in excitatory neurons of this region could participate in mediating the antinociceptive actions of S1P.
Dihydro-S1P inhibits the cAMP-dependent phosphorylation of NMDA receptors in the spinal cord
To test whether the activation of S1P receptors modulates cAMP-dependent nociceptive signaling in the outer laminae of the dorsal horn, we studied the effect of intrathecally administered dihydro-S1P on PKA-dependent phosphorylation (serine 897) of N-methyl-D-aspartate (NMDA) receptors. of This NMDA receptor phosphorylation is enhanced during the second phase of the formalin assay and serves to sensitize NMDA receptors in the dorsal horn (40, 41) . We intrathecally administered dihydro-S1P and determined its effect on the PKAdependent phosphorylation of the NMDA receptor subunit 1 (NR1) on serine 897. In accordance with previous reports NR1 phosphorylation on serine 897 in the outer laminae of the dorsal horn was increased in the formalin assay (40, 41) (Fig. 6A,B) . Intrathecally administered dihydro-S1P reduced NR1 phosphorylation on serine 897 below basal levels (Fig. 6A,B) suggesting an inhibition of the cAMP/PKA signaling pathway. Next, we determined the influence of intrathecally administered dihydro-S1P on a calcium-dependent phosphorylation. Here we monitored the formalininduced phosphorylation of the Ca 2+ /calmodulin regulated kinase II (CamKII) on threonine 286. As described previously (42) , formalin injection in the hind paws induced an increased phosphorylation of CamKII in the outer laminae of the dorsal horn (Fig. 6C,D) . Importantly, the effect of dihydro-S1P on the formalin-induced CamKII phosphorylation was much less pronounced than its effect on NR1 phosphorylation (Fig. 6B,D) .
DISCUSSION
We show in this report that alterations in the spinal S1P concentrations modulate spinal nociceptive processing. Lowered spinal S1P concentrations decreased basal pain thresholds and, conversely, increased spinal S1P concentrations reduce painrelated behavior. Surprisingly, the antinociceptive effect of intrathecally applied S1P disappeared when high S1P doses were administered. Since dihydro-S1P, which does not possess the second messenger properties of S1P (25, 27) , exhibited a linear dose-dependency even at very high doses, the data suggest that the intracellular signaling properties of S1P cause the loss of antinociceptive efficacy. Accordingly, while both sphingolipids exhibited identical potencies towards the receptormediated inhibition of the neuronal cAMP accumulation, only S1P (10 µM) was able to instigate a calcium response in spinal cord neurons. Thus, the data suggest that the loss of the antinociceptive properties of S1P at high doses is based on its uptake in neurons which then might enhance nociceptive processing (12, 26) . The notion that S1P receptor activation in the spinal cord has antinociceptive effects is further supported by a previous study that demonstrates that intrathecal application of the S1P receptor agonist FTY720 decreases pain-related behavior in the formalin test (43) . The role of the cAMP-dependent signaling pathways in regulation of neuronal excitability and the pro-nociceptive effects of increased spinal cAMP concentrations are well established. It has been demonstrated that intrathecally applied cAMPanalogues as well as the adenylyl cyclase activator forskolin produce an enhanced response to noxious stimuli (hyperalgesia) (28) while inhibitors of cAMP-phosphodiesterases prolong hyperalgesia (28, 29) . Moreover, agents that decrease cAMP levels, such as opioids and adenosine, inhibit hyperalgesia (30, 31) . In accordance with these findings adenylyl cyclase knockout mice show reduced behavioral responses in several pain models (44, 45) as well as a reduced response to opioids (46, 47) . At the cellular and molecular level the hyperalgesic effect of cAMP is mainly mediated by PKA (32) . PKA phosphorylates multiple targets during central sensitization (i.e. NR1 and glycin receptor α 3 (GlyRα3) (48,49) ), thereby augmenting neuronal excitability and nociceptive processing. Here we describe that S1P-treatment inhibits the cAMP synthesis in excitatory neurons of laminae II and III of the spinal cord. The inhibition of cAMP signaling in excitatory neurons of this region would most likely reduce nociceptive processing, since primary afferents (37) as well as GABAergic neurons terminate in these laminae (38) and dendrites of excitatory neurons of laminae III enter the superficial laminae (39) . These excitatory neurons are also a major target for substance P-containing (nociceptive) primary afferents (39) . The finding that S1P treatment decreases cAMP synthesis in neurons in these laminae is supported by the observation that intrathecally administered dihydro-S1P abolished the formalin-induced, cAMP-dependent phosphorylation of NR1 in the outer laminae of the dorsal horn while the calcium-dependent, formalininduced CamKII phosphorylation was only partially reduced. Such a partial reduction of the CamKII phosphorylation level is expected, since reduction of spinal nociceptive processing through inhibition of cAMP-dependent sensitization processes would also influence nociception-related calciumdependent signaling pathways. However, additional neuronal and non-neuronal cell types, which were not identified by our experimental approach, might participate in the antinociceptive effects of S1P. In this regard we showed that S1P and dihydro-S1P elevate at physiological concentrations intracellular calcium concentrations in glia cells. In summary we describe here that intrathecal administration of S1P decreases the nociceptive behavior in the formalin assay and that reduced spinal S1P concentrations lower basal pain thresholds. In conjunction with the finding that peripheral nociceptive stimuli decrease S1P levels in the cerebrospinal fluid, these data are the first evidence for a role of S1P in spinal nociceptive processing. It is tantalizing to speculate that as part of the nociceptive system S1P may suppress nociceptive signaling in absence of nociceptive stimuli by inhibiting the cAMP synthesis in excitatory neurons. In this scenario reduced S1P concentrations would contribute as part of the nociceptive system to the facilitation of nociceptive signaling by disinhibition of cAMP-dependent signaling pathways. However, it will be necessary to identify the specific S1P receptor(s) that mediate the antinociceptive actions of S1P in the spinal cord as soon as the necessary tools such as selective S1P receptor agonists or viable conditional S1P receptor knockout mice without behavioral abnormalities are available. Finally, since S1P facilitates the NGFinduced increases in the excitability of cultured DRG neurons (11, 12) , our findings point towards a multifaceted role of S1P in nociceptive processing. . Cells that responded to S1P or dihydro-S1P (dhS1P) with increased intracellular calcium concentrations are shown as percentage of the total cell number. Student's t-test: *P<0.05, **P<0.01 ***P<0.001. E. Calcium imaging of spinal cord neurons after incubation with 10 µM S1P. Fluorescence ratios of 17 neurons that respond to S1P (grey) and 11 non-responding neurons (black) are shown as mean + S.E.M. KCl was given by puff application, S1P by bath application. 
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